Haemacure gets Hemaseel trial approval:
This article was originally published in Clinica
Executive Summary
Haemacure has been given approval by the FDA to begin a Phase II trial of its Hemaseel biological tissue glue. The adhesive is a liquid derived from human plasma which is a capable of stopping bleeding. The company, based in Montreal, Canada, intends to demonstrate the efficacy of its glue to control post-surgical bleeding and will begin the trial in the US later this month. US company ClinTrials Research is managing the study.